Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Share-based Compensation (2016 - 2025)

Ultragenyx Pharmaceutical has reported Share-based Compensation over the past 10 years, most recently at $37.3 million for Q4 2025.

  • Quarterly Share-based Compensation fell 7.09% to $37.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $152.8 million through Dec 2025, down 3.28% year-over-year, with the annual reading at $153.0 million for FY2025, 3.16% down from the prior year.
  • Share-based Compensation was $37.3 million for Q4 2025 at Ultragenyx Pharmaceutical, up from $37.0 million in the prior quarter.
  • Over five years, Share-based Compensation peaked at $41.6 million in Q3 2024 and troughed at $24.3 million in Q1 2021.
  • The 5-year median for Share-based Compensation is $35.3 million (2022), against an average of $34.1 million.
  • Year-over-year, Share-based Compensation surged 32.69% in 2021 and then dropped 10.97% in 2025.
  • A 5-year view of Share-based Compensation shows it stood at $26.8 million in 2021, then rose by 9.35% to $29.4 million in 2022, then increased by 14.18% to $33.5 million in 2023, then grew by 19.74% to $40.1 million in 2024, then decreased by 7.09% to $37.3 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Share-based Compensation are $37.3 million (Q4 2025), $37.0 million (Q3 2025), and $38.6 million (Q2 2025).